Novo Nordisk NVO announced that it has ended its collaboration with telehealth provider Hims & Hers Health. In addition, the ...

After consistently failing to meet investor expectations, Novo Nordisk touted a safety profile for CagriSema in line with the ...

Presenting results from the REDEFINE 1 and REDEFINE 2 studies at the American Diabetes Association (ADA) congress in Chicago, ...

Novo Nordisk's CagriSema achieved significant weight loss in phase 3 trials, though safety concerns may limit its edge over ...

Separately, Novo Nordisk presented early data for its oral amycretin program. In Phase I and Ib/IIa trials, amycretin ...

By Maggie Fick and Stine Jacobsen LONDON/COPENHAGEN (Reuters) -Shares in Novo Nordisk fell as much as 3.5% on Monday after ...

Results from the Phase III REDEFINE 1 trial show that CagriSema led to a 22.7% mean weight reduction at 68 weeks in adults ...

CNW/ – This week, The New England Journal of Medicine (NEJM) published results from Novo Nordisk’s phase 3 REDEFINE 1 trial ...

Novo Nordisk’s next-gen weight loss drug and Zepbound “seem fairly equal to me,” one expert says after release of new ...

Novo Nordisk shares tumble 5.6% after ending Hims & Hers partnership and releasing disappointing CagriSema obesity drug trial ...

Novo Nordisk presented trial results from its trials evaluating the efficacy of CagriSema, another weight-loss drug. Patients ...

The combination of once-weekly cagrilintide 2.4 mg and semaglutide 2.4 mg conferred greater weight loss at 68 weeks compared ...